Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles

ACS Nano

Volumn 7, Issue 11, 2013, Pages 9558-9570

  Barua, Sutapa ^a   Mitragotri, Samir ^a  

^a University of California   (United States)

Author keywords

camptothecin; doxorubicin; herceptin; morphology; nanoparticle; shape; synergistic

Indexed keywords

CAMPTOTHECIN (CPT); DOXORUBICIN; HERCEPTIN; SHAPE; SYNERGISTIC;

BODY FLUIDS; CELL MEMBRANES; CYTOLOGY; DESIGN; MONOCLONAL ANTIBODIES; MORPHOLOGY; NANORODS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; DRUG CARRIER; MONOCLONAL ANTIBODY; NANOPARTICLE; NANOTUBE; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CELL CYCLE; CELL MEMBRANE; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DRUG EFFECT; FEMALE; HUMAN; IC 50; METHODOLOGY; NANOMEDICINE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; CYTOPLASM; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; NANOMEDICINE; NANOPARTICLES; NANOTUBES;

EID: 84888858196     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn403913k     Document Type: Article

References (79)

1. Sun, B.; Ranganathan, B.; Feng, S.-S. Multifunctional Poly(d, l-lactide-co-glycolide)/Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer Biomaterials 2008, 29, 475-486 (Pubitemid 350110345)
2. Choi, C. H. J.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of Active Targeting in Solid Tumors with Transferrin-Containing Gold Nanoparticles Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 1235-1240
3. Mi, Y.; Liu, X.; Zhao, J.; Ding, J.; Feng, S. S. Multimodality Treatment of Cancer with Herceptin Conjugated, Thermomagnetic Iron Oxides and Docetaxel Loaded Nanoparticles of Biodegradable Polymers Biomaterials 2012, 33, 7519-7529
4. Fabbro, C.; Ali-Boucetta, H.; Ros, T. D.; Kostarelos, K.; Bianco, A.; Prato, M. Targeting Carbon Nanotubes against Cancer Chem. Commun. 2012, 48, 3911-3926
5. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. In Vivo Cancer Targeting and Imaging with Semiconductor Quantum Dots Nat. Biotechnol. 2004, 22, 969-976 (Pubitemid 39014473)
6. Koo, O. M.; Rubinstein, I.; Onyuksel, H. Camptothecin in Sterically Stabilized Phospholipid Micelles: A Novel Nanomedicine Nanomedicine 2005, 1, 77-84 (Pubitemid 43963604)
7. Wang, Z.; Yu, Y.; Dai, W.; Lu, J.; Cui, J.; Wu, H.; Yuan, L.; Zhang, H.; Wang, X.; Wang, J. et al. The Use of a Tumor Metastasis Targeting Peptide To Deliver Doxorubicin-Containing Liposomes to Highly Metastatic Cancer Biomaterials 2012, 33, 8451-8460
8. Tsai, C.-P.; Chen, C.-Y.; Hung, Y.; Chang, F.-H.; Mou, C.-Y. Monoclonal Antibody-Functionalized Mesoporous Silica Nanoparticles (MSN) for Selective Targeting Breast Cancer Cells J. Mater. Chem. 2009, 19, 5737-5743
9. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting Cancer Cells Using PLGA Nanoparticles Surface Modified with Monoclonal Antibody J. Controlled Release 2007, 120, 18-26 (Pubitemid 46874614)
10. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in Vivo Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6315-6320
11. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C. Quantum Dot-Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer Nano Lett. 2007, 7, 3065-3070 (Pubitemid 350132931)
12. Xiao, Z.; Levy-Nissenbaum, E.; Alexis, F.; Lupták, A.; Teply, B. A.; Chan, J. M.; Shi, J.; Digga, E.; Cheng, J.; Langer, R. et al. Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection ACS Nano 2012, 6, 696-704
13. Dam, D. H. M.; Lee, J. H.; Sisco, P. N.; Co, D. T.; Zhang, M.; Wasielewski, M. R.; Odom, T. W. Direct Observation of Nanoparticle-Cancer Cell Nucleus Interactions ACS Nano 2012, 6, 3318-3326
14. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs Science 2010, 328, 1031-1035
15. Howarth, M.; Takao, K.; Hayashi, Y.; Ting, A. Y. Targeting Quantum Dots to Surface Proteins in Living Cells with Biotin Ligase Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7583-7588 (Pubitemid 40741014)
16. Zhang, S.; Li, J.; Lykotrafitis, G.; Bao, G.; Suresh, S. Size-Dependent Endocytosis of Nanoparticles Adv. Biomater. 2009, 21, 419-424
17. Yoo, J.-W.; Doshi, N.; Mitragotri, S. Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry Macromol. Rapid Commun. 2010, 31, 142-148
18. Gratton, S. E.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The Effect of Particle Design on Cellular Internalization Pathways Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11613-11618
19. Vácha, R.; Martinez-Veracoechea, F. J.; Frenkel, D. Receptor-Mediated Endocytosis of Nanoparticles of Various Shapes Nano Lett. 2011, 11, 5391-5395
20. Barua, S.; Yoo, J. W.; Kolhar, P.; Wakankar, A.; Gokarn, Y. R.; Mitragotri, S. Particle Shape Enhances Specificity of Antibody-Displaying Nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3270-3275
21. Harush-Frenkel, O.; Debotton, N.; Benita, S.; Altschuler, Y. Targeting of Nanoparticles to the Clathrin-Mediated Endocytic Pathway Biochem. Biophys. Res. Commun. 2007, 353, 26-32 (Pubitemid 44958337)
22. Austin, C. D.; De Mazière, A. M.; Pisacane, P. I.; van Dijk, S. M.; Eigenbrot, C.; Sliwkowski, M. X.; Klumperman, J.; Scheller, R. H. Endocytosis and Sorting of Erbb2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin Mol. Biol. Cell 2004, 15, 5268-5282 (Pubitemid 39564723)
23. Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S. Ligand Binding and Kinetics of Folate Receptor Recycling in Vivo: Impact on Receptor-Mediated Drug Delivery Mol. Pharmacol. 2004, 66, 1406-1414 (Pubitemid 39564767)
24. Zhang, L.; Xia, J.; Zhao, Q.; Liu, L.; Zhang, Z. Functional Graphene Oxide as a Nanocarrier for Controlled Loading and Targeted Delivery of Mixed Anticancer Drugs Small 2010, 6, 537-544
25. Sahoo, S. K.; Ma, W.; Labhasetwar, V. Efficacy of Transferrin-Conjugated Paclitaxel-Loaded Nanoparticles in a Murine Model of Prostate Cancer Int. J. Cancer 2004, 112, 335-340 (Pubitemid 39244375)
26. Sahoo, S. K.; Labhasetwar, V. Enhanced Antiproliferative Activity of Transferrin-Conjugated Paclitaxel-Loaded Nanoparticles Is Mediated via Sustained Intracellular Drug Retention Mol. Pharmaceutics 2005, 2, 373-383 (Pubitemid 41503678)
27. Jaxel, C.; Capranico, G.; Kerrigan, D.; Kohn, K. W.; Pommier, Y. Effect of Local DNA Sequence on Topoisomerase I Cleavage in the Presence or Absence of Camptothecin J. Biol. Chem. 1991, 266, 20418-20423 (Pubitemid 21908475)
28. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity Cancer Res. 1989, 49, 1465-1469 (Pubitemid 19088683)
29. Staker, B. L.; Feese, M. D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A. B. Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I-DNA Covalent Complex J. Med. Chem. 2005, 48, 2336-2345 (Pubitemid 40516428)
30. Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limentani, S.; Tan-Chiu, E.; Krop, I. E.; Michaelson, R. A.; Girish, S. et al. Phase II Study of the Antibody Drug Conjugate Trastuzumab-Dm1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (Her2)-Positive Breast Cancer after Prior Her2-Directed Therapy J. Clin. Oncol. 2011, 29, 398-405
31. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M. et al. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of Her2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol. 2002, 20, 719-726 (Pubitemid 34111379)
32. Cobleigh, M. A.; Vogel, C. L.; Tripathy, D.; Robert, N. J.; Scholl, S.; Fehrenbacher, L.; Wolter, J. M.; Paton, V.; Shak, S.; Lieberman, G. et al. Multinational Study of the Efficacy and Safety of Humanized Anti-Her2 Monoclonal Antibody in Women Who Have Her2-Overexpressing Metastatic Breast Cancer That Has Progressed after Chemotherapy for Metastatic Disease J. Clin. Oncol. 1999, 17, 2639
33. Croxtall, J. D.; McKeage, K. Trastuzumab: In Her2-Positive Metastatic Gastric Cancer Drugs 2010, 70, 2259-2267
34. Bang, Y.-J.; Van Cutsem, E.; Feyereislova, A.; Chung, H. C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T. et al. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of Her2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (Toga): A Phase 3, Open-Label, Randomised Controlled Trial Lancet 2010, 376, 687-697
35. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M. et al. Use of Chemotherapy Plus a Monoclonal Antibody against Her2 for Metastatic Breast Cancer That Overexpresses Her2 N. Engl. J. Med. 2001, 344, 783-792 (Pubitemid 32222155)
36. Burstein, H. J.; Harris, L. N.; Gelman, R.; Lester, S. C.; Nunes, R. A.; Kaelin, C. M.; Parker, L. M.; Ellisen, L. W.; Kuter, I.; Gadd, M. A. et al. Preoperative Therapy with Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for Her2 Overexpressing Stage II or III Breast Cancer: A Pilot Study J. Clin. Oncol. 2003, 21, 46-53
37. Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; Chan, S.; Grimes, D.; Antón, A.; Lluch, A. et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group J. Clin. Oncol. 2005, 23, 4265-4274 (Pubitemid 46207001)
38. Jackisch, C. Her-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy Oncologist 2006, 11, 34-41
39. Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer, C. E.; Davidson, N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A. et al. Trastuzumab Plus Adjuvant Chemotherapy for Operable Her2-Positive Breast Cancer N. Engl. J. Med. 2005, 353, 1673-1684 (Pubitemid 41464706)
40. Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA Topoisomerase II-Mediated Interaction of Doxorubicin and Daunorubicin Congeners with DNA Cancer Res. 1989, 49, 5969-5978 (Pubitemid 19274156)
41. Blum, R. H.; Carter, S. K. Adriamycin Ann. Intern. Med. 1974, 80, 249-259
42. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev. 2004, 56, 185-229 (Pubitemid 38720829)
43. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K. et al. Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogs: Inhibition of Topoisomerase I and Antitumor Activity J. Med. Chem. 1991, 34, 98-107
44. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M. et al. Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I J. Med. Chem. 1995, 38, 395-401
45. Nawara, K.; Romiszewski, J.; Kijewska, K.; Szczytko, J.; Twardowski, A.; Mazur, M.; Krysinski, P. Adsorption of Doxorubicin onto Citrate-Stabilized Magnetic Nanoparticles J. Phys. Chem. C 2012, 116, 5598-5609
46. Pommier, Y.; Redon, C.; Rao, V. A.; Seiler, J. A.; Sordet, O.; Takemura, H.; Antony, S.; Meng, L.; Liao, Z.; Kohlhagen, G. et al. Repair of and Checkpoint Response to Topoisomerase I-Mediated DNA Damage Mutat. Res., Fundam. Mol. Mech. Mutagen. 2003, 532, 173-203 (Pubitemid 37487853)
47. Chou, T.-C.; Talalay, P. Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
48. Dean-Colomb, W.; Esteva, F. J. Her2-Positive Breast Cancer: Herceptin and Beyond Eur. J. Cancer 2008, 44, 2806-2812
49. Hsiang, Y.-H.; Lihou, M. G.; Liu, L. F. Arrest of Replication Forks by Drug-Stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin Cancer Res. 1989, 49, 5077-5082 (Pubitemid 19239347)
50. Ling, Y. H.; el-Naggar, A. K.; Priebe, W.; Perez-Soler, R. Cell Cycle-Dependent Cytotoxicity, G2/M Phase Arrest, and Disruption of P34cdc2/Cyclin B1 Activity Induced by Doxorubicin in Synchronized P388 Cells Mol. Pharmacol. 1996, 49, 832-841
51. Chen, J.; Irudayaraj, J. Quantitative Investigation of Compartmentalized Dynamics of Erbb2 Targeting Gold Nanorods in Live Cells by Single Molecule Spectroscopy ACS Nano 2009, 3, 4071-4079
52. Colin, J. T.; Anna, C. R.; Krysten, J. P.; Thomas, W.; Jacqueline, O.; Naomi, A.; Jez, G. C.; Joachim, K.; David, J. S.; Peter, J. C. Snx4 Coordinates Endosomal Sorting of Tfnr with Dynein-Mediated Transport into the Endocytic Recycling Compartment Nat. Cell Biol. 2007, 9, 1370-1380
53. Humblet, V.; Misra, P.; Bhushan, K. R.; Nasr, K.; Ko, Y.-S.; Tsukamoto, T.; Pannier, N.; Frangioni, J. V.; Maison, W. Multivalent Scaffolds for Affinity Maturation of Small Molecule Cell Surface Binders and Their Application to Prostate Tumor Targeting J. Med. Chem. 2009, 52, 544-550
54. Decuzzi, P.; Ferrari, M. The Adhesive Strength of Non-spherical Particles Mediated by Specific Interactions Biomaterials 2006, 27, 5307-5314 (Pubitemid 44080296)
55. Decuzzi, P.; Ferrari, M. The Receptor-Mediated Endocytosis of Nonspherical Particles Biophys. J. 2008, 94, 3790-3797
56. Muro, S.; Garnacho, C.; Champion, J. A.; Leferovich, J.; Gajewski, C.; Schuchman, E. H.; Mitragotri, S.; Muzykantov, V. R. Control of Endothelial Targeting and Intracellular Delivery of Therapeutic Enzymes by Modulating the Size and Shape of Icam-1-Targeted Carriers Mol. Ther. 2008, 16, 1450-1458
57. Jin, H.; Heller, D. A.; Sharma, R.; Strano, M. S. Size-Dependent Cellular Uptake and Expulsion of Single-Walled Carbon Nanotubes: Single Particle Tracking and a Generic Uptake Model for Nanoparticles ACS Nano 2009, 3, 149-158
58. Park, J.-H.; von Maltzahn, G.; Zhang, L.; Derfus, A. M.; Simberg, D.; Harris, T. J.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Systematic Surface Engineering of Magnetic Nanoworms for In Vivo Tumor Targeting Small 2009, 5, 694-700
59. Huang, X.; Teng, X.; Chen, D.; Tang, F.; He, J. The Effect of the Shape of Mesoporous Silica Nanoparticles on Cellular Uptake and Cell Function Biomaterials 2010, 31, 438-448
60. Kolhar, P.; Mitragotri, S. Polymer Microparticles Exhibit Size and Shape Dependent Accumulation around the Nucleus after Endocytosis Adv. Funct. Mater. 2012, 22, 3759-3764
61. Xu, Z. P.; Niebert, M.; Porazik, K.; Walker, T. L.; Cooper, H. M.; Middelberg, A. P. J.; Gray, P. P.; Bartlett, P. F.; Lu, G. Q. Subcellular Compartment Targeting of Layered Double Hydroxide Nanoparticles J. Controlled Release 2008, 130, 86-94
62. Croce, A. C.; Bottiroli, G.; Supino, R.; Favini, E.; Zuco, V.; Zunino, F. Subcellular Localization of the Camptothecin Analogues, Topotecan and Gimatecan Biochem. Pharmacol. 2004, 67, 1035-1045 (Pubitemid 38296783)
63. Poon, I. K. H.; Jans, D. A. Regulation of Nuclear Transport: Central Role in Development and Transformation? Traffic 2005, 6, 173-186 (Pubitemid 40298152)
64. Misra, R.; Sahoo, S. K. Intracellular Trafficking of Nuclear Localization Signal Conjugated Nanoparticles for Cancer Therapy Eur. J. Pharm. Sci. 2010, 39, 152-163
65. Yu, J.; Xie, X.; Zheng, M.; Yu, L.; Zhang, L.; Zhao, J.; Jiang, D.; Che, X. Fabrication and Characterization of Nuclear Localization Signal-Conjugated Glycol Chitosan Micelles for Improving the Nuclear Delivery of Doxorubicin Int. J. Nanomed. 2012, 7, 5079-5090
66. Gillies, E. R.; Fréchet, J. M. J. pH-Responsive Copolymer Assemblies for Controlled Release of Doxorubicin Bioconjugate Chem. 2005, 16, 361-368 (Pubitemid 40388212)
67. Dong, D.-W.; Tong, S.-W.; Qi, X.-R. Comparative Studies of Polyethylenimine-Doxorubicin Conjugates with pH-Sensitive and pH-Insensitive Linkers J. Biomed. Mater. Res., Part A 2013, 101A, 1336-1344
68. Dalmark, M.; Johansen, P. Molecular Association between Doxorubicin (Adriamycin) and DNA-Derived Bases, Nucleosides, Nucleotides, Other Aromatic Compounds, and Proteins in Aqueous Solution Mol. Pharmacol. 1982, 22, 158-165 (Pubitemid 12097277)
69. Mohan, P.; Rapoport, N. Doxorubicin as a Molecular Nanotheranostic Agent: Effect of Doxorubicin Encapsulation in Micelles or Nanoemulsions on the Ultrasound-Mediated Intracellular Delivery and Nuclear Trafficking Mol. Pharmaceutics 2010, 7, 1959-1973
70. Robert, J.; Illiadis, A.; Hoerni, B.; Cano, J.-P.; Durand, M.; Lagarde, C. Pharmacokinetics of Adriamycin in Patients with Breast Cancer: Correlation between Pharmacokinetic Parameters and Clinical Short-Term Response Eur. J. Cancer Clin. Oncol. 1982, 18, 739-745 (Pubitemid 12033227)
71. Potter, A. J.; Gollahon, K. A.; Palanca, B. J. A.; Harbert, M. J.; Choi, Y. M.; Moskovitz, A. H.; Potter, J. D.; Rabinovitch, P. S. Flow Cytometric Analysis of the Cell Cycle Phase Specificity of DNA Damage Induced by Radiation, Hydrogen Peroxide and Doxorubicin Carcinogenesis 2002, 23, 389-401 (Pubitemid 34257618)
72. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata1,2 J. Am. Chem. Soc. 1966, 88, 3888-3890
73. Junttila, T. T.; Akita, R. W.; Parsons, K.; Fields, C.; Lewis Phillips, G. D.; Friedman, L. S.; Sampath, D.; Sliwkowski, M. X. Ligand-Independent Her2/Her3/Pi3k Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the Pi3k Inhibitor Gdc-0941 Cancer Cell 2009, 15, 429-440
74. Laginha, K. M.; Verwoert, S.; Charrois, G. J. R.; Allen, T. M. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors Clin. Cancer Res. 2005, 11, 6944-6949 (Pubitemid 41428752)
75. De Jong, W. H.; Hagens, W. I.; Krystek, P.; Burger, M. C.; Sips, A. J. A. M.; Geertsma, R. E. Particle Size-Dependent Organ Distribution of Gold Nanoparticles after Intravenous Administration Biomaterials 2008, 29, 1912-1919
76. Wiegand, S.; Heinen, T.; Ramaswamy, A.; Sesterhenn, A. M.; Bergemann, C.; Werner, J. A.; Lübbe, A. S. Evaluation of the Tolerance and Distribution of Intravenously Applied Ferrofluid Particles of 250 and 500 nm Size in an Animal Model J. Drug Targeting 2009, 17, 194-199
77. Hyung Park, J.; Kwon, S.; Lee, M.; Chung, H.; Kim, J.-H.; Kim, Y.-S.; Park, R.-W.; Kim, I.-S.; Bong Seo, S.; Kwon, I. C. et al. Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing Hydrophobic Moieties as Carriers for Doxorubicin: In Vivo Biodistribution and Anti-tumor Activity Biomaterials 2006, 27, 119-126 (Pubitemid 41225375)
78. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size Cancer Res. 1995, 55, 3752-3756
79. Kolhar, P.; Anselmo, A. C.; Gupta, V.; Pant, K.; Prabhakarpandian, B.; Ruoslahti, E.; Mitragotri, S. Using Shape Effects To Target Antibody-Coated Nanoparticles to Lung and Brain Endothelium Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 10753-10758